<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142902">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01875484</url>
  </required_header>
  <id_info>
    <org_study_id>2012CB518603</org_study_id>
    <nct_id>NCT01875484</nct_id>
  </id_info>
  <brief_title>Circulating miR-126 as a Novel Biomarker for Post Myocardial Infarction Remodeling</brief_title>
  <acronym>PMIR-miR-126</acronym>
  <official_title>Impact of Circulating miR-126 on Left Ventricular Remodeling and Clinical Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention. The PMIR-miR-126 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qianfoshan Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinan Central Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital of Shanghai Jiaotong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital</source>
  <oversight_info>
    <authority>China: National Natural Science Foundation</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The purpose of this study is to evaluate the impact of circulating miR-126 on left
      ventricular remodeling and clinical outcomes in patients undergoing primary percutaneous
      coronary intervention for ST-segment elevation myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in LVEDV from baseline by 2D-echocardiogram</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome of this study will be the change from baseline in left ventricular end diastolic volume (LVEDV) at 6 months post-PCI by 2D-echocardiogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events (MACE)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiovascular  death, myocardial infarction, target vessel revascularization,recurrent ischaemia, heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVESV from baseline</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in left ventricular end systolic volume (LVESV), ejection fraction (LVEF) and mass at 6 months post-PCI by 2D-echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP levels</measure>
    <time_frame>at 1 and 180 days post-PCI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complete ST-segment resolution</measure>
    <time_frame>3 hours after PCI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak troponin T level</measure>
    <time_frame>24 hours after PCI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Left Ventricular Remodeling</condition>
  <condition>miR-126</condition>
  <arm_group>
    <arm_group_label>High miR-126 group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate miR-126 group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Low miR-126 group</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples: serum, plasma, RNA, DNA, microRNAs, CD34+ cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients undergoing primary PCI for STEMI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted for primary PCI for STEMI involving the LAD within 12 hours of  onset of
             symptoms. STEMI will be defined as typical ECG changes (ST segment elevation ≥2mm in
             2 or more precordial leads) associated with acute chest pain or an elevation of
             cardiac enzymes;

          -  Age ≥18 years;

          -  Informed consent from patient or next of kin.

        Exclusion Criteria:

          -  Nonischaemic Cardiomyopathy;

          -  Cardiac surgery planed in the 6 months;

          -  Mechanical complication of STEMI (ventricular septal rupture, free wall rupture,
             acute severe mitral regurgitation);

          -  Renal or hepatic failure;

          -  Malignancy, HIV, or central nervous system disorder;

          -  Cardiopulmonary resuscitation &gt;15 min and compromised level of consciousness;

          -  Cardiogenic shock;

          -  Current participation in any research study involving investigational drugs or
             devices;

          -  No written consensus;

          -  Previous myocardial infarction.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pan-Pan Hao, MD, PhD</last_name>
    <phone>86-15098934185</phone>
    <email>panda.how@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Zhong Li, MD</last_name>
      <email>llliuyanping@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhi-Zhong Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panpan Hao, MD, PhD</last_name>
      <phone>86-15098934185</phone>
    </contact>
    <investigator>
      <last_name>Cheng Zhang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun Zhang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan-Ping Liu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Guo Chen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Xiang Zhang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pan-Pan Hao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Wei Zhang, MD, PhD</last_name>
      <email>zmw1983@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Ming-Wei Zhang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xin Zhang, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qianfoshan Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei-Xin Hu, MM</last_name>
      <email>hpx.0418@163.com</email>
    </contact>
    <investigator>
      <last_name>Pei-Xin Hu, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bin Li, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Qingdao University Medical College</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Shan, MD, PhD</last_name>
      <email>270387320@QQ.COM</email>
    </contact>
    <investigator>
      <last_name>Liang Shan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Han, MM</last_name>
      <email>896530560@QQ.com</email>
    </contact>
    <investigator>
      <last_name>Hui Han, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 11, 2013</lastchanged_date>
  <firstreceived_date>May 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital</investigator_affiliation>
    <investigator_full_name>Yun Zhang</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>miR-126</keyword>
  <keyword>Left Ventricular Remodeling</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>primary percutaneous coronary intervention</keyword>
  <keyword>left ventricular end diastolic volume</keyword>
  <keyword>left ventricular ejection fraction</keyword>
  <keyword>major adverse cardiovascular events</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
